SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Wilma Mankiller — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientWilma Mankiller
Date of birth1945-11-18
IdentifiersMRN HR-ML052-SYN-TD; SSN (made up) 000-52-4183
Document date1980-03-23
AuthorRena Hawkfeather-Lindqvist, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review: antibody, nerve stimulation and imaging results; neuromuscular neurology seen today. [S]

History of Present Illness

Ms. Mankiller returns two weeks after her first visit. On pyridostigmine 30 mg three times daily her eyelids lift for two to three hours after each dose, but double vision returns by evening and her arms still tire when she brushes her hair; she has mild stomach cramps and looser stools after doses. She has had no breathlessness, choking or weak cough. The acetylcholine receptor antibody test is strongly positive. The chest CT and kidney ultrasound were done last week. This morning she saw Dr. Okafor-Delaney of neuromuscular neurology, whose nerve stimulation test showed the typical decrement, and they agreed a plan: a higher pyridostigmine dose, prednisone started low and raised slowly, azathioprine once the screening tests are back, and an assessment for thymectomy. She asked that her blood tests be drawn near home where possible, and wants to understand each medicine before she takes it. She says the polycystic kidney disease is not new to her. [S]

ElementDetail
DiagnosisGeneralized myasthenia gravis, AChR antibody 6.8 nmol/L, decrement on nerve stimulation; MGFA class IIa; MG-ADL 7
ImagingNo thymoma on chest CT; kidney ultrasound: polycystic kidneys, Mayo Imaging Class 1B
Starting todayPyridostigmine 60 mg four times daily; prednisone 10 mg rising weekly; calcium and vitamin D
Vaccines todayPCV20 and recombinant zoster dose 1, before immunosuppression

Review of Systems

SystemResultFinding
EyesPositiveDrooping eyelids and double vision by evening
MusculoskeletalPositiveArms and neck tire with use; leg aches after the operations
GastrointestinalPositiveCramps and loose stools after pyridostigmine; no trouble swallowing
RespiratoryNegativeNo breathlessness lying flat; cough strong
PsychiatricNegativeWorried but coping; PHQ-2 score 1

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Pyridostigmine bromide 30 mg oral tablet, one tablet three times daily with meals as a trial; take 30 to 45 minutes before eatingOne tablet three times dailyOral route1980-03-09 to 1980-03-23completedS
Pyridostigmine bromide 60 mg oral tablet, one tablet four times daily while awake, 30 to 45 minutes before mealsOne tablet four times daily while awakeOral route1980-03-23 to 1980-10-12completedS
Prednisone 10 mg oral tablet, 10 mg each morning, rising by 10 mg each week to 40 mg each morning, then held at 40 mgOnce each morning; dose as directedOral route1980-03-23 to 1980-07-13completedS
Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet daily with foodOne tablet daily with foodOral route1980-03-23activeS
Cholecalciferol (vitamin D3) 1000 units (0.025 mg) oral tablet, one tablet dailyOne tablet dailyOral route1980-03-23activeS
Acetaminophen 500 mg oral tablet, one or two tablets up to three times daily as needed for leg painOne or two tablets up to three times daily as neededOral route1979-09-15activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1980-03-23Body height163cmS
1980-03-23Body weight61.6kgS
1980-03-23Body mass index (BMI) [Ratio]23.2kg/m2S
1980-03-23Systolic blood pressure124mm[Hg]S
1980-03-23Diastolic blood pressure80mm[Hg]S
1980-03-23Heart rate76/minS
1980-03-23Respiratory rate16/minS
1980-03-23Body temperature36.6CelS
1980-03-23Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1980-03-23Acetylcholine receptor binding Ab [Moles/volume] in Serum6.8nmol/L0.02 nmol/L or less is negativeHighS
1980-03-23Forced vital capacity [Volume] Respiratory system3.25LLower limit of normal about 2.9 L for her age, sex and heightNormalS
1980-03-23Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S

Physical Exam

Vital signs recorded on 1980-03-23; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 124/80 mm Hg
EyesLeft ptosis after 40 seconds of upgaze; diplopia on sustained right gaze
NeurologicalNeck flexion 4 of 5; deltoids fatigue after 45 seconds of arm abduction; speech becomes nasal after counting to 40; reflexes normal
RespiratorySingle-breath count to 30; FVC 3.25 L

Problems

ProblemClinical statusVerificationCodeProvenance
Drooping eyelids and double vision for six weeks, worse in the evening, with fatigable weakness of the arms and neck, tiring when chewing and a nasal voice after long talks; a disorder of the neuromuscular junction suspectedresolvedconfirmed H53.2S — Synthetic presenting problem, resolved at the second visit when antibodies and nerve testing established myasthenia gravis.
Generalized myasthenia gravis, acetylcholine receptor antibody positive, MGFA class IIa, without thymoma; synthetic modern detail linked to her documented myasthenia gravis of 1934activeconfirmed G70.00S — Synthetic antibody level, electrodiagnosis, class and treatment; the diagnosis less than a year after the crash, and recovery with Cherokee medicine people, surgery and drug therapy, are documented (D).
Autosomal dominant polycystic kidney disease (hereditary, as she has described it), with normal kidney function; to be stagedactiveconfirmed Q61.2S — The hereditary polycystic kidney disease is documented (D) from her later public account; its detection before the index date, and every value, are synthetic.
Recovery from major trauma in a head-on car crash last year: fractures of both legs, ribs and face, with many operations; walks independently, with a cane on rough groundactiveconfirmed Z87.81S — The crash, the operations and the injuries are documented (D); the current function is synthetic.
Long-term glucocorticoid therapy for myasthenia gravis, with monitoring of glucose, blood pressure, weight, bone health, mood, sleep, eyes and infectionactiveconfirmed Z79.52S — Synthetic treatment plan.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryAcetylcholine receptor binding antibodiesAt diagnosisCompleted today6.8 nmol/L, positive (drawn at the first visit)
LaboratoryMuSK antibodiesIf AChR antibodies are negativeNot indicatedAChR antibodies positive
ExaminationRepetitive nerve stimulationAt diagnosisCompleted today22 percent decrement in the nasalis and 18 percent in the trapezius at neuromuscular neurology
ExaminationSingle-fiber EMGIf antibodies and nerve stimulation are not diagnosticNot indicatedDiagnosis already confirmed
ImagingCT of the chest for thymomaAt diagnosisUp to dateFive days ago: no thymoma; residual thymic tissue for age
LaboratoryTSHAt diagnosisUp to date1.9 mIU/L at the first visit
ImagingForced vital capacity and negative inspiratory forceEvery visit while weak, and with any breathing or swallowing symptomCompleted todayFVC 3.25 L; negative inspiratory force -68 cm H2O; single-breath count 30
ExaminationMyasthenic crisis warning signsEvery visitCompleted todayNo breathlessness lying flat, weak cough, choking or slurred speech; reviewed again with her
SurveyMG-ADL scoreEvery visitCompleted today7 of 24 (eyelids, double vision, chewing, brushing hair); no LOINC code, so recorded here
SurveyDepression screen (PHQ-2)At intervalsCompleted todayPHQ-2 score 1
Medication safetyPyridostigmine side effectsEvery visitCompleted todayCramps and loose stools, mild; taken before meals
Medication safetyMedicines that can worsen myasthenia gravisAt diagnosis and with every new prescriptionCompleted todayWallet card and list given: fluoroquinolones, aminoglycosides, macrolides, magnesium by vein, beta-blockers, telithromycin and others
LaboratoryScreening before immunosuppression: hepatitis B, tuberculosis and TPMTBefore azathioprineOrderedDrawn today at the clinic
LaboratoryHemoglobin A1c before glucocorticoidsBaseline, then periodicallyUp to date5.3 percent at the first visit
Medication safetyVaccination before immunosuppressionBefore starting immunosuppressive drugsCompleted todayPCV20 and recombinant zoster dose 1 today; no live vaccines from now on
Medication safetyPregnancy and contraception on prednisone and azathioprineBefore starting and yearlyCompleted todayUrine pregnancy test negative; she reports reliable contraception; pregnancy to be planned with neuromuscular neurology
LaboratoryeGFR and urine albumin-to-creatinine ratioYearly in ADPKD with normal functionUp to dateeGFR 102 and urine albumin 14 mg/g at the first visit
ImagingKidney imaging with total kidney volume (Mayo Imaging Classification)At diagnosis or first assessmentUp to dateUltrasound five days ago: htTKV 364 mL/m, class 1B; tolvaptan not indicated
ExaminationBlood pressureEvery visitCompleted today124/80 mm Hg in clinic; home readings to start
ReferralNeuromuscular neurologyOnce, then through treatmentCompleted todaySeen today; recommendations in the consultation note
ReferralThoracic surgery for thymectomyOnce stableOrderedAssessment visit in about four weeks
Self-managementHome blood pressure, water intake, salt, and care close to homeEvery visitCompleted todayHome monitor shown; blood tests to be drawn at the Cherokee Nation clinic near her home where possible

Goal progress:

Immunizations given today: Pneumococcal conjugate vaccine PCV20, before immunosuppression; Recombinant zoster vaccine, dose 1 of 2, before immunosuppression [S]

Guideline basis: Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020); Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); Cautionary Drugs (medicines that may worsen myasthenia gravis) (2026); KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int 2025;107(2S):S1-S239 (2025)

Follow-up: Neuromuscular neurology nurse call in one week as prednisone rises. Thoracic surgery assessment in about four weeks. Review here in six weeks with blood count, chemistry, FVC and DXA. Next scheduled visit 1980-05-04: six-week review on pyridostigmine and prednisone: strength, breathing, glucose and blood pressure, bone density, start of azathioprine, and the thymectomy plan. [S]